Friends of Cancer Research has launched a collaboration that aims to address concerns about the lack of consistency in determining homologous recombination deficiency—HRD—status, its prognostic value, and its use as a predictive biomarker.
At a time when federal immigration policies are becoming stricter, Kunle Odunsi, director of University of Chicago Medicine Comprehensive Cancer Center, reflected on the fact that cancer research is a highly international community.
